Ministry of Health and Prevention recalls non-conforming batch of API Sinocort Nasal Spray

Dubai UAE

Sallam Sallam

The Ministry of Health and Prevention, MoHAP, announced that it has withdrawn one batch of the API Sinocort Nasal Spray used for the treatment of asthma and blocked airways. The decision was made after having reviewed the study reports of the approved specifications of the drug and that the analysis showed that the batch doesn’t conform to those specifications.

The ministry accordingly issued a circular to directors of medical districts, public and private hospitals, physicians, pharmacists, assistant pharmacists, and directors of government and private pharmacies to withdraw one batch of this generic drug manufactured by Amman Jordan Pharmaceutical Industries with batch number ME051.

This comes as part of the Ministry’s efforts to strengthen quality and health safety as per the international standards.

Instructions to drug suppliers, healthcare practitioners, and pharmacists

His Excellency Dr. Amin Hussein Al Amiri, the Assistant Undersecretary of the Ministry of Health and Prevention’s Public Health Policy and Licenses, Chairman of the Supreme National Committee for Pharmacovigilance, explained that the circular is requesting the drug supplier to withdraw the non-conforming batch from the public and private sector and is asking healthcare practitioners not to prescribe it, as well as pharmacists to stop selling the said batch and returning it to the drug supplier.

He urged community members to report any adverse effects of the batch, if used, via the following email: [email protected] or through the E-system on MoHAP’s website, or the smart app ‘UAE RADAR’, noting that all drug-related circulars are available on the ministry’s website.

He further urged the individuals to dispose of the said batch, if any, and to consult with their attending physicians to prescribe conforming batches of the medicine, emphasizing MoHAP’s commitment to protecting the health and safety of the society and that the Pharmacovigilance Committee is constantly communicating with international drug authorities, as well as local and international pharmaceutical companies to keep up to date with the updates of drug-related safety warnings.